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The prevalence of laryngeal involvement in Rheumatoid Arthritis (RA) ranges from 13 to 75%. 
The specific RA manifestations include the cricoarytenoid arthritis and the presence of rheumatoid 
nodules in the vocal folds.
Objective: The objective of this study is to evaluate the prevalence of dysphonia and laryngeal 
alterations on videolaryngoscopy in RA patients and their association with disease activity.
Method: This is a clinical cross-sectional study that evaluated patients with rheumatoid arthritis 
as to their disease activity score in 28 joints (DAS-28), laryngeal symptoms, application of a Portu-
guese version of the Voice Handicap Index and videolaryngoscopy findings, comparing them with 
a control group.
Results: We evaluated 47 (54%) patients with rheumatoid arthritis and 40 (46%) controls. The preva-
lence of dysphonia and videolaryngoscopy changes was respectively 12.8% and 72.4% in patients 
with RA. The mean of DAS-28 was 3.3 ± 1.2; 26 (74.3%) of 35 patients presenting active disease had 
laryngeal changes (p = 0.713). Posterior laryngitis was the most common diagnosis (44.7%).
Conclusion: The prevalence of laryngeal disorders in RA patients was 72.4% and the prevalence 
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, autoimmune 
disease, of unknown cause, which affects mainly women 
between 30 and 50 years of age1,2. The world prevalence 
in the adult population is approximately 0.5% to 1%, and 
the incidence is of 20 to 50 cases per 100,000 people 
annualy1-3. RA represents joint manifestations as well as 
extra-joint manifestations, which may potentially happen 
to any diarthrodial joint, including the cricoarythenoid4.
The prevalence of laryngeal repercussions in RA 
is 13% to 75%5,6 in different studies and, specifically, in 
post-mortem studies, which is of 45% to 88%6. Knowledge 
on the laryngeal involvement in RA patients is longstan-
ding: the changes were described by Mackenzie, in 1880, 
by means of studies in cadavers, and the first studies using 
laryngoscopy happened in 19606.
Laryngeal manifestations in RA patients are usually 
subclinical5 and benign6. Initial symptoms are hoarseness, 
globus pharyngeus and the sensation of having a foreign 
body in the throat. Afterwards, patients experience ody-
nophagia, sore throat, cough and dyspnea5. Dysphonia 
happens to 12% to 27% of the patients with RA, and the 
relative risk of dysphonia varies between 3 and 4 when 
compared to healthy patients7.
About 66% of the laryngeal symptoms in RA 
patients are related to cricoarytenoid joint involvement8. 
Cricoarytenoid arthritis is a potential cause of acute 
obstruction of the airways9-11, compromising vocal fold 
mobility and causing edema, which requires tracheostomy12. 
Other laryngeal alterations typical of RA are rheumatoid 
nodules, which may be mild, diagnosed only through 
micro-videolaryngoscopy or through histopathology, or 
until they become exuberant, in a bamboo shape13-15. 
Although bamboo nodules are not pathognomonic of RA, 
they are highly suggestive of autoimmune diseases, such 
as systemic erythematous lupus, Hashimoto’s thyroiditis, 
Sjögren’s syndrome and autoimmune hepatitis14-16. 
Autoimmune diseases may also cause yellow-whitish 
deposits, with the appearance of convex bands on the 
surface of the vocal folds, that is, macroscopically similar 
to rheumatoid nodules. Rheumatoid nodules are also part 
of the differential diagnosis of laryngeal cysts16.
Laryngeal repercussions of RA involve different 
specific knowledge from very distinct medical specialties: 
Otorhinolaryngology and Rheumatology. Notwithstanding, 
a large part of the papers on this topic are limited to 
case reports or are associated with small patient samples. 
Voulgari et al.6 reinforced the need for more prospective 
studies in different communities on the otorhinolaryngo-
logical and laryngeal involvements in RA. In Brazil, the 
knowledge regarding RA manifestations in the larynx, as 
well as its respective statistical data is limited. The goal 
of this study is to assess the prevalence of dysphonia and 
laryngeal changes upon videolaryngoscopy in RA patients 
and association with the disease’s degree of activity.
METHOD
This study was approved by the Ethics in Research 
with Human Beings Committee of the Federal University 
of Santa Catarina, under protocol number 1654. There is 
no disclaimer regarding this paper. This is an observatio-
nal, analytical and cross-sectional study of 87 patients, 47 
with RA in the study group and 40 patients in the control 
group. The patients were randomly invited to participate 
in the study and were assessed between March of 2011 
and March of 2012. The individuals signed the Informed 
Consent Form, according to the guidelines and regulatory 
standards of research involving human beings.
Series
Inclusion criteria in the study group were: the pa-
tient having a diagnosis of RA according to the American 
College of Rheumatology (ACR) criteria of 198717. In the 
control group we had patients referred for videolaryngos-
copy exams in the otolaryngology Ward of the University 
Hospital - UFSC, whom could have dysphonia and other 
laryngeal complaints in general, or not.
We took off the study group those patients with 
juvenile rheumatoid arthritis, since this form of disease 
has many clinical and laboratorial characteristics which 
are peculiar to rheumatoid arthritis in itself. In the control 
group we took off those patients with a confirmed diag-
nosis or a suspicion of RA.
Instruments utilized
In both groups we first did an interview, which aim 
was to assess gender, age, proton pump inhibitors (PPI), 
smoking/smoking load and the presence of laryngeal 
symptoms in general, such as cough, dyspnea, hawking, 
globus pharyngeus, throat pain or irritation, vocal fatigue.
We followed by deploying the Voice Handicap 
Index (VHI) questionnaire in its translated and adapted 
version into Brazilian Portuguese by Jotz & Dornelles18. VHI 
is a vocal capacity self-assessment questionnaire, created 
with the aim of measuring the difficulties experienced by 
individuals with vocal disorders. The patients answered a 
total of 30 questions, equally divided, encompassing three 
aspects (functional, physical and emotional). The patients 
could answer the questions with never (no points), almost 
never (1 point), sometimes (2 points), almost always (3 
points) and always (4 points), which if added up could 
make up a total between zero and 120 points. The cutting 
point on establishing dysphonia was 15 points in the total 
VHI scale, as well as in the study by Speyer et al.7.
In the RA group, we also assessed disease time 
and score. The Disease Activity Score 28 (DAS-28)19 is 
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a disease-activity index which assesses 28 joints in RA 
patients: it is obtained considering the number of painful 
joints and those with edema, erythrocyte sedimentation 
rate (ESR) and the assessment of the patient’s general he-
alth. In order to establish this last parameter, the patient 
is asked how he/she feels regarding his/her arthritis: the 
patient would assign a value according to the scale in 
which 0 means very well and 100, very bad. According to 
the result obtained, we considered the patient in remit-
tance, should the value be lower than 2.6; higher values 
represent some degree of disease activity20.
In the sequence, the patients were submitted to 
videolaryngoscopy, which was carried out with the 8mm 
70º rigid telescope, coupled to the halogen Sigmed® FL250 
light source and a Toshiba® micro camera. Stroboscopy 
was not utilized. The 10% lidocaine spray was used in 
the patients’ oropharynx when needed. The videolaryn-
goscopy exams were always done by the same examiner.
The database was built using the Epidata®, version 
3.1 software, with consistency and amplitude automatic 
control. Following that, the data was exported to the 
Stata® statistical package version 11.2, in which we did the 
statistical analysis. The data description was expressed as 
absolute and relative frequencies. We then adopted the 5% 
(p < 0.05) significance value (p-value) for bicaudal tests. 
All the comparisons carried out between proportions were 
evaluated through the Fisher’s exact test.
RESULTS
In the group of RA patients, 40 (85.1%) were fema-
les versus 26 (65.0%) of the patients in the control group. 
Mean age was 56.5 ± 12.6 years in the RA group, and in 
the control group it was 47.9 ± 13.6 years. PPI was used 
by 35 (74.5%) of the patients in this group, and by eight 
(20.0%) of the patients in the control group, (p = 0.00). 
Eight (17%) patients with RA were also smokers versus 10 
(25%) in the control group, (p = 0.43). The mean smoking 
load was 8.44 and 8.75 years/pack, respectively, between 
patients with RA and those in the control group.
Concerning laryngeal symptoms of patients with 
RA, 38 (80.9%) reported at least one symptom (Table 1) 
and nine (19.2%) of them denied having all the symp-
toms listed in the protocol. No patient in the sample 
reported stridor.
Regarding the index suggesting the presence of 
dysphonia, the mean VHI among RA patients was 6.36 ± 
10.82 points. In the control group, the mean was 13.15 
points ± 13.78. VHI was higher than 15 points, characte-
rizing dysphonia, in six (12.8%) of the patients with RA, 
and in 12 (30.0%) of the patients in the control group, 
(p = 0.064). Therefore, the ratio of dysphonia prevalen-
ce among patients in the RA group vis-à-vis the control 
group was 0.42.
In the RA group of patients we could see that the 
mean time between the disease diagnosis was 15.3 ± 8.6 
years. Considering the degree of disease activity, the DAS-
28 mean value was 3.34 ± 1.17. The DAS-28 was lower 
than 2.6 points in 12 (25.5%) patients, and higher than this 
cutting value in 35 (74.5%) cases.
The prevalence of videolaryngoscopy alterations 
in RA patients was 72.3% and, in the control group it was 
65.0% (Table 2). Thus, the ratio of prevalence of such 
changes among patients in the RA group and that of those 
in the control group was 1.1.
The videolaryngoscopy diagnostics in RA patients 
was detailed and compared with the occurrence of patients 
from the control group (Table 3). One patient from the 
RA group had unilateral vocal fold paralysis. She repor-
ted chronic dysphonia since she was submitted to total 
thyroidectomy, a manifestation of a probable damage to 
the recurrent laryngeal nerve.
We found different types of glottic clefts in RA pa-
tients: 10 (21.3%) patients had posterior triangular glottic 
clefts, three (6.4%) with the medium-posterior, one (2.1%) 
with a spindle-shaped cleft and one (2.1%) with a dou-
ble cleft. One (2.5%) patient in the control group had a 
spindle-shape cleft.
As to the association of altered videolaryngoscopy 
and disease duration, 13 (27.75) patients had disease 
duration of less than 15 years, of whom 11 (84.6%) had 
normal videolaryngoscopy. Of the 34 (72.3%) patients with 
disease duration longer than 15 years, 18 (52.9%) had some 
type of change seen upon videolaryngoscopy (p = 0.025).
A total of 26 (74.3%) patients of the 35 with DAS-28 
> 2.6 had some type of disorder seen upon the videolaryn-
goscopy, (p = 0.713). Twenty-nine (85.3%) patients with 
laryngeal disorders had VHI < 15 points, and five (14.7%) 
of the patients who had laryngeal alterations had VHI < 15 
points, (p = 1.00).
DISCUSSION
Both dysphonia and RA may compromise an 
individual’s quality of life. There are just a few papers in the 
Brazilian medical literature discussing laryngeal changes 
and dysphonia in patients with RA. Since RA is a disease 
characterized by a course of remission and activity1,2, it 
is important to correlate the videolaryngoscopy findings 
with the patients’ clinical condition.
The RA patients in this study had moderate disease 
activity19,20, with a DAS-28 score lower than what has been 
found in other populations. Corbacho et al.21, Avelar et 
al.22 and Ranzolin et al.23 found DAS-28 scores equal to 
4.68 ± 1.79; 6.33 ± 0.92 and 4.23 ± 1.2 points. There are no 
studies assessing the DAS-28 relationship with the laryn-
geal changes. It is known that there is a direct association 
between the degree of disease activity and the joint and 
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Table 1. List of the laryngeal symptoms of the patients.
Laryngeal symptoms
Rheumatoid arthritis Control group
p
n % n %
Dyspnea 08 17.02 09 22.5 0.59
Cough 22 46.81 21 52.50 0.66
Hawking 22 46.81 22 55.00 0.52
Globus pharyngeus 80 17.02 17 42.50 0.01
Throat irritation 12 25.52 14 35.00 0.35
Odynophagia 04 8.51 09 23.08 0.07
Vocal fatigue 06 12.77 14 35.00 0.02
Table 2. Distribution of the videolaryngoscopy results.
Videolaryngoscopy
Normal Altered
n % n %
RA Group 13 27.7 34 72.3
Control Group 14 35 26 65
Table 3. List of diagnosis upon videolaryngoscopy.
Videolaryngoscopy diagnosis Rheumatoid arthritis Control group p
Normal
n % n %
0.49
13 27.6 14 35
Diffuse chronic laryngitis 07 14.89 10 25 0.28
Posterior laryngitis 21 44.68 13 32.5 0.27
Glottic cleft 15 31.92 01 2.5 0
Vocal nodule(s) 01 2.13 0 0 1.00
Presbylaryngitis 01 2.13 0 0 1.00
Unilateral vocal fold paralysis 01 2.13 01 2.5 1.00
extra-joint clinical repercussion severity arising from the 
RA inflammation20.
The VHI result was lower in patients with RA (6.36 ± 
10.82) vis-à-vis the control group patients (13.15 ± 13.78). 
The prevalence of results higher than 15 points - cutting 
point utilized by Speyer et al.7, suggesting dysphonia, 
was 42.3% lower in patients with RA when compared to 
the control group; however, this data was not statistically 
significant (p = 0.064).
Considering a recent American study assessing 55 
million patients24, which pointed to a dysphonia prevalen-
ce in the population equal to 0.98%, one may infer that 
dysphonia in RA individuals is more prevalent than in the 
general population; however, it is less prevalent in relation 
to patients with laryngeal diseases and no RA. Thus, RA 
or its treatment may somehow impair voice production.
As to the remaining laryngeal symptoms, those 
patients in the control group had more vocal fatigue 
and globus pharyngeus than the patients with RA, and 
both occurrences were statistically significant (p = 0.02 
and p = 0.01, respectively). Dyspnea and throat irritation 
were symptoms reported by patients from both groups 
at a similar rate (p = 0.59 and p = 0.35, respectively). Stri-
dor was not reported by the patients, since it is a severe 
symptom - predictor of airway obstruction9,12, which is not 
expected in ambulatory care level.
The prevalence of laryngeal alterations in RA 
patients was 72.3% and the probability of detecting 
changes upon videolaryngoscopy was 10% higher in RA 
patients when compared to those in the control group. 
The laryngeal alterations happened mostly to RA patients 
who had had the disease for over 15 years - value equal 
to that of the mean time of diagnosis, and the disease time 
higher than the mean was statistically significant in detec-
ting laryngeal alterations in patients with RA (p = 0.025). 
Despite the cases reporting laryngeal involvement in RA 
patients with at least 10 years with the disease9,11,18, in the 
literature there is nothing saying that longer time duration 
of RA is a risk factor for laryngeal alterations. Results of 
VHI higher than or equal to 15 points were not statistically 
significant in relation to the laryngeal alterations seen upon 
videolaryngoscopy (p = 1.00).
The laryngeal alterations present in patients with RA 
did not correspond to the specific laryngeal involvement 
caused by the disease, represented by cricoarytenoid 
arthritis and by rheumatoid nodules of the vocal folds6,8,13,14. 
None of the patients had cricoarytenoid arthritis and only 
one patient (2.1%) had vocal nodules. Nevertheless, we 
noticed that the laryngeal alterations in RA patients were 
similar to the ones found in patients with laryngeal dise-
ases without RA. Thus, we may infer that RA and/or the 
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drugs utilized to treat this disease may affect the larynx 
in an unspecific fashion. However, such changes did not 
cause so much dysphonia in RA patients as in the control 
group, indicating that other symptoms, such as hawking, 
globus pharyngeus and cough must suggest to the clinician 
a possible laryngeal involvement.
In patients with RA, posterior laryngitis was the most 
prevalent videolaryngoscopy-related diagnosis (44.7%), 
with a percentage value higher than the one found in the 
control group (32.5%); however, without statistical signifi-
cance (p = 0.27). Posterior laryngitis is a common alteration 
caused by laryngopharyngeal reflux (LPR)25. In parallel to 
that, cough and hawking, the most prevalent symptoms in 
RA patients in this study, although non-specific, may also 
be explained by the laryngeal and pharyngeal exposure 
to the acid content from the stomach or some irritative 
factor26. Cough and Hawking were not significant in RA 
patients (p = 0.66 and p = 0.52).
PPI are important drugs in the treatment of LPR25,26 
and they are broadly utilized by RA patients (74%) (p = 0) 
because of their chronic use of non-hormonal anti-inflam-
matory agents1,2,27. Nevertheless, despite the use of PPI, 
posterior laryngitis was considered an important diagnosis 
in RA patients. In parallel to that, diffuse chronic laryngitis, 
arising from the persistence of some laryngeal mucosa 
irritative factor28, such as LPR, was found in almost 15% 
of the patients with RA. However, this prevalence was 
significantly lower when compared to the one found 
in the control group (25%) and there was no statistical 
significance (p = 0.28).
Although they do not represent RA-specific laryn-
geal alterations, glottic clefts were found mainly in these 
patients (31.9%), all in females, having a relevant statis-
tical significance (p = 0) vis-à-vis the control group. The 
glottis proportion - relationship between the length of 
the membranous and cartilaginous portions of the vocal 
folds, is an important determining factor of glottic clefts: 
it may be reduced or enlarged - depending on gender, 
age and vocal abuse29. Presbylarynx, a type of glottic cleft 
in the elderly30, was found in a 67-year old patient with 
RA. Thus, since the clefts are not described as alterations 
pertaining to RA, they may have happened mainly in RA 
patients, given the female predominance31 in this group.
This study showed that laryngeal symptoms and 
laryngeal alterations are frequent in RA patients: which 
may indicate that RA and/or its treatment may somehow 
have laryngeal repercussions, even when the symptoms 
or morphological laryngeal involvement is not considered 
to be specific of RA.
CONCLUSION
The prevalence of dysphonia, established by the VHI, 
and laryngeal alterations seen upon videolaryngoscopy 
were 12.8% and 72.3% in RA patients, respectively. The 
relationship between laryngeal alterations and the degree 
of disease activity was not established.
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